Table 2.
Characteristics of included studies in the meta-analysis (no MSCs group)
| Author (publication year) | Study design | Recruitment period | Number of patients | Median age | Sex (M/F) | Type | Conditioning regimen | GVHD prophylaxis | Interval from diagnosis to treatment (M) | Neutrophil recovery (d) | Platelet engraftment | MSCs originals | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhang YY [56] (2020) | Single-arm study | January 2013-Septemper 2018 | 35 | 43 (40–54) | 23/11 | SAA/VSAA (19/16) | BU + CY + ATG | CsA + MMF + MTX | NA | 13 (9–21) | 17 (10–102) | NA | 6 |
| Ma YR [55] (2020) | Single-arm study | NA | 199 | NA | 106/93 | NA | BU + CY + ATG | CsA + MMF + MTX | NA | NA | NA | NA | 6 |
| Liu LM [54] (2020) | Single-arm study | Septemper 2010-Septemper 2018 | 16 | 32 (8–55) | 9/7 | NA | ATG + rituximab | NA | NA | 11 (9–20) | 21 (13–112) | NA | 6 |
| Yang SW [22] (2019) | Single-arm study | NA | 32 | NA | 21/11 | NA | NA | NA | NA | NA | NA | NA | 6 |
| Xu LP5 [53] (2019) | Single-arm study | 2006–2018 | 392 | NA | 223/167 | NA | BU + CY + ATG | CsA + MMF + MTX | NA | 12 (9–31) | 14 (5–180) | NA | 6 |
| Hyery Kim [52] (2019) | Single-arm study | 2008–2017 | 32 | 12.7 (1.4–21.7) | 22/10 | SAA/VSAA (20/12) | FLU, CY, ATG ± TBI | CsA + MMF | 5.2 (1.2–106.8) | 10 (9–30) | 15.5 (13–60) | NA | 5 |
| Lu Y [51] (2018) | Single-arm study | Septemper 2012-Septemper 2016 | 41 | 13 (4–42) | 25/16 | SAA/VSAA(28/13) | FLU, CY, ATG | CsA + MMF + MTX | 25 (6–45) | 14 (10–21) | 13 (3–56) | NA | 6 |
| Sung-Eun Lee [24] (2018) | Single-arm study | June 2012-December 2016 | 34 | 31.5 (17–59) | 20/14 | SAA/VSAA (11/23) | ATG + TBI + FLU | CsA + MTX | NA | 12 (11–12) | 14 (5–86) | NA | 5 |
| Cheng YF [50] (2018) | Single-arm study | December 2007-Septemper 2016 | 28 | NA | NA | NA | NA | NA | 2.75 (1–8) | 12 (10–21) | NA | NA | 6 |
| Cao LQ [49] (2018) | Single-arm study | January 2006-December 2016 | 131 | 16 (2–45) | 70/61 | NA | NA | NA | NA | 12 (10–31) | 16 (7–276) | NA | 5 |
| Zhang P [48] (2017) | Single-arm study | June 2014-December 2015 | 8 | 14 (5–26) | 5/3 | NA | FLU, CY, ALG/TBI | CsA + MMF + MTX | NA | 14.8 (11–20) | 15.0 (11–21) | NA | 6 |
| Zhang Y [47] (2017) | Single-arm study | June 2010-December 2014 | 18 | NA | NA | NA | NA | NA | NA | 16 (12–26) | 20 (17–35) | NA | 5 |
| Pei XY [46] (2017) | Single-arm study | January 2008-December 2015 | 81 | 14 (3–45) | 50/31 | SAA/VSAA (63/18) | NA | NA | NA | 12 (10–22) | 15 (7–150) | NA | 6 |
| Sarita Rani Jaiswal [45] (2017) | Single-arm study | January 2015-May 2016 | 20 | NA | NA | NA | FLU, CY, ATG, melphalan | PTCy + sirolimus + CsA + MMF (abatacept) | NA | NA | NA | NA | 5 |
| Amy E. DeZern [44](2017) | Single-arm study | July 2011-August 2016 | 13 | 33 (11–69) | 9/5 | NA | FLU, CY, ATG ± TBI | PTCy+MMF + FK506 | NA | 19 (16–27) | 28 (22–108) | NA | 5 |
| Zhu H [43] (2016) | Single-arm study | July 2002-November 2013 | 38 | NA | 12/24 | SAA/VSAA (8/28) | FLU, CY, ATG ± TBI/BU | CsA + methotrexate (MTX) (n = 12) CsA + MTX + mycophenolate mofetil (MMF) (n = 22) MTX + tacrolimus (n = 4) | NA | NA | NA | NA | 6 |
| Liu L [42] (2016) | Single-arm study | July 2005-December 2013 | 26 | 26 (10–54) | 15/11 | SAA/VSAA/(16/6) | NA | NA | NA | 12 (6–28) | 19 (12–330) | NA | 5 |
| Ho Joon Im [41] (2015) | Single-arm study | NA | 21 | 14 (3–21) | NA | NA | FLU, CY, ATG ± TBI | NA | NA | NA | NA | NA | 6 |
| Esteves I [25] (2015) | Single-arm study | July 2010-August 2014 | 16 | 17 (5–39) | 11/5 | NA | CY + FLU+ TBI, FLU + ATG (2) | MMF, CsA, Cy | NA | 19 (16–29) | 21 (20–29) | NA | 6 |
| Gao L [40] (2014) | Single-arm study | June 2007-December 2010 | 26 | 25.4 (18–41) | NA | SAA/VSAA (16/10) | FLU, CY, ATG | CsA + MMF + MTX + ATG | NA | 13 (11–19) | 13 (10–21) | NA | 5 |
| Jennifer Clay [39] (2014) | Single-arm study | NA | 8 | NA | NA | NA | CY + FLU + TBI | MMF + FLU + PTCY | NA | 18.5 (16–23) | 26 (21–27) | NA | 5 |
Abbreviations: SAA severe aplastic anemia, VSAA very severe aplastic anemia, ATG antithymoglobulin, CsA cyclosporin A, MSCs bone marrow-mesenchymal stem cells, haplo-HSCT haplo-identical hematopoietic stem cell transplantation, BU busulfan, Cy cyclophosphamide, MMF mycophenolate mofetil, FLU fludarabine, MTX methotrexate, GVHD graft-versus-host disease, TBI total body irradiation